TSBX

Investor Moves

Investor	Portfolio Value	Portfolio Change	Position Change	Avg Buy Price	Current Price
Steven CohenPoint72 $-293.3K ExitQ3 2025 $293k -- --
Steven CohenPoint72 $-293.3K ExitQ3 2025 $293k -- --
Jim SimonsRenaissance Technologies $-16.9K ExitQ3 2025 $17k -- --
Jim SimonsRenaissance Technologies $-16.9K ExitQ3 2025 $17k -- --
Steven CohenPoint72 $-67.1K TrimQ2 2025 $67k -- --
Steven CohenPoint72 $-67.1K TrimQ2 2025 $67k -- --

Trade TSBX

About Turnstone Biologics Corp.

Turnstone Biologics Corp. is a clinical-stage biotechnology firm dedicated to developing therapeutic and curative treatments for patients battling solid tumor cancers. Its leading investigational drug, TIDAL-01, is currently undergoing Phase 1 clinical trials for indications such as breast cancer, colorectal cancer, and uveal melanoma. This compound is also being assessed in an investigator-sponsored trial to address cutaneous and non-cutaneous melanomas. Furthermore, the company is advancing TIDAL-02, which is in preclinical development for treating various solid tumors. Turnstone Biologics was established in 2014 and maintains its headquarters in La Jolla, California.

CEO: Sammy J. Farah
IPO Date: Jul 21, 2023

Market Data

Open: $0.355
High: $0.355
Low: $0.355
Volume: 283.8K
52W High: $2.26
52W Low: $0.29

Valuation

Valuation snapshot is not available yet.

Financials

Financial statement snapshot is not available yet.

Events

EarningsAug 8

EPS est. -0.16 · actual -0.24